N-α-[1-carboxy-3-(3-indolyl)-propyl]-L-lysyl-L-proline | 79155-13-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-α-[1-carboxy-3-(3-indolyl)-propyl]-L-lysyl-L-proline
• 英文别名: (2S)-1-[(2S)-6-amino-2-[[1-carboxy-3-(1H-indol-3-yl)propyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid
• CAS: 79155-13-8；79155-14-9；85955-63-1
• 化学式: C₂₃H₃₂N₄O₅
• 分子量: 444.531
• InChiKey: BJEMKCYXIFCBBN-WMEOFMBSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.7
• 重原子数：
  32
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  149
• 氢给体数：
  5
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  3-吲哚丙酸 在 palladium on activated charcoal sodium hydroxide 、 四甲基乙二胺 、 氢气 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 生成 N-α-[1-carboxy-3-(3-indolyl)-propyl]-L-lysyl-L-proline
  参考文献：
  名称：

  A one-step synthesis of ethyl 4-(β-indolyl)-2-ketobutyrate via polyanion chemistry and its conversion into angiotensin converting enzyme inhibitors

  摘要：

  DOI：

  10.1016/s0040-4039(01)92927-2

文献信息

• Process for preparation of carboxyalkyldipeptide derivatives
  申请人：Merck & Co., Inc.

  公开号：EP0079521A1

  公开（公告）日：1983-05-25

  A process for the preparation of carboxyalkyldipeptide compounds of the Formula is described wherein R6 is hydroxy, loweralkoxy, or amino; R, R2 and R7 are hydrogen or loweralkyl; R3 is, e.g., hydrogen, or loweralkyl, R' is, e.g., hydrogen, or alkyl of from 1 to 20 carbon atoms, R4 is hydrogen or loweralkyl, R5 is, e.g., hydrogen, or loweralkyl, and, R4 and R5 may be connected together to form an alyklene bridge of from 2 to 4 carbon atoms. The process comprises reacting a compound of the Formula with a dipeptide (or protected dipeptide) of the Formula and an alkali metal cyanide or a trimethylsilycyanide, to form an amino nitrile compound of the Formula followed by hydrolysis. These compounds are useful as converting enzyme inhibitors and as antihypertensive agents.

  描述了一种制备Formula的羧基烷基二肽化合物的过程，其中R6为羟基、低烷氧基或氨基；R、R2和R7为氢或低烷基；R3为氢、低烷基等；R'为氢、1-20碳原子的烷基等；R4为氢或低烷基；R5为氢、低烷基等，R4和R5可以连接在一起形成2-4个碳原子的烷基桥。该过程包括将Formula的化合物与Formula的二肽（或保护的二肽）和碱金属氰化物或三甲基硅氰化物反应，形成Formula的氨基腈化合物，然后进行水解。这些化合物可用作转化酶抑制剂和降压剂。
• Carboxyalkyl dipeptide derivatives, process for preparing them and pharmaceutical composition containing them
  申请人：Merck & Co., Inc.

  公开号：EP0012401A1

  公开（公告）日：1980-06-25

  Carboxyalkyl dipeptide derivatives and related compounds which are useful as antihypertensives, and having the formulae: wherein R and R6 are the same or different and are hydroxy, alkoxy, alkenoxy, dialkylamino alkoxy, acylamino alkoxy, acyloxy alkoxy, aryloxy, alkyloxy, substituted aryloxy or substituted aralkoxy wherein the substituent is methyl, halo, or niethoxy, amino, alkylamino, dialkylamino, aralkylamino or hydroxyamino; R1 is hydrogen, alkyl of from 1 to 20 carbon atoms, including branched, cyclic and unsaturated alkyl groups; substituted alkyl wherein the substituent is halo, hydroxy, alkoxy, aryloxy amino, alkylamino, dialkylamino, acylamino, arylamino, guanidino, imidazolyl, indolyl, mercapto, alkylthio, arylthio, carboxy, carboxamido, carbalkoxy, phenyl, substituted phenyl wherein the substituent is alkyl, alkoxy or halo; aralkyl or heteroaralkyl, aralkenyl or heteroaralkenyl, substituted aralkyl, substituted heteroaralkyl, substituted aralkenyl or substituted hetereoaralkenyl, wherein the substituent is halo or dihalo, alkyl, hydroxy, alkoxy, amino, aminomethyl, acylamino, dialkylamino, alkylamino, carboxyl, haloalkyl, cyano or sulfonamido, aralkyl or hetereoaralkyl substituted on the alkyl portion by amino or acylamino; R2 and R7 are hydrogen or alkyl; R3 is hydrogen, alkyl, phenylalkyl, aminomethylphenyl- alkyl, hydroxyphenylalkyl, hydroxyalkyl, acetylaminoalkyl, acylaminoalkyl, acylaminoalkyl aminoalkyl, dimethyl- aminoalkyl, haloalkyl, guanidinoalkyl, imidazolylalkyl, indolylalkyl, mercaptoalkyl and aikylthioalkyl; R4 is hydrogen or alkyl; R5 is hydrogen, alkyl, phenyl, phenylalkyl, hydroxyphenylalkyl, hydroxyalkyl, aminoalkyl, guanidinoalkyl, imidazolylalkyl, indolylalkyl, mercaptoalkyl or alkylthioalkyl; R and R5 may be connected together to form an alkylene bridge of from 2 to 4 carbon atoms, an alkylene bridge of from 2 to 3 carbon atoms and one sulphur atom, an alkylene bridge of from 3 to 4 carbon atoms containing a double bond or an alkylene bridge as above, substituted with hydroxy, alkoxy or alkyl and the pharmaceutically acceptable salts thereof.

  可用作抗高血压药的羧烷基二肽衍生物及相关化合物，其式如下 其中 R 和 R6 相同或不同，并且是羟基、烷氧基、烯氧基、二烷基氨基烷氧基、酰氨基烷氧基、酰氧基烷氧基、芳氧基、烷氧基、取代的芳氧基或取代的烷氧基，其中取代基是甲基、卤代或二乙氧基、氨基、烷基氨基、二烷基氨基、芳基氨基或羟基氨基； R1 是氢、1 至 20 个碳原子的烷基，包括支链、环状和不饱和烷基； 取代基为卤素、羟基、烷氧基、芳氧基氨基、烷基氨基、二烷基氨基、酰基氨基、芳基氨基、胍基、咪唑基、吲哚基、巯基、烷硫基、芳硫基、羧基、羧酰胺基、羰基烷氧基、苯基、取代基为烷基、烷氧基或卤素的取代苯基；芳烷基或杂烷基、芳烯基或杂芳烯基、取代的芳烷基、取代的杂烷基、取代的芳烯基或取代的对位芳烯基，其中取代基为卤代或二卤代、烷基、羟基、烷氧基、氨基、氨甲基、酰氨基、二烷基氨基、烷基氨基、羧基、卤代烷基、氰基或磺酰氨基，烷基部分被氨基或酰氨基取代的芳烷基或对位芳烷基； R2 和 R7 是氢或烷基； R3 是氢、烷基、苯基烷基、氨甲基苯基烷基、羟基苯基烷基、羟基烷基、乙酰氨基烷基、酰氨基烷基、酰氨基烷基氨基烷基、二甲基氨基烷基、卤代烷基、胍基烷基、咪唑基烷基、吲哚基烷基、巯基烷基和烷硫基烷基； R4 是氢或烷基 R5 是氢、烷基、苯基、苯基烷基、羟苯基烷基、羟基烷基、氨基烷基、胍基烷基、咪唑基烷基、吲哚基烷基、巯基烷基或硫代烷基； R 和 R5 可连接在一起，形成 2 至 4 个碳原子的亚烷基桥、2 至 3 个碳原子和一个硫原子的亚烷基桥、含有双键的 3 至 4 个碳原子的亚烷基桥或被羟基、烷氧基或烷基取代的上述亚烷基桥及其药学上可接受的盐。
• Prostaglandin antagonists
  申请人：MERCK FROSST CANADA INC.

  公开号：EP0140784A2

  公开（公告）日：1985-05-08

  This invention deals with the compounds of the formulae: wherein Z is thio, sulfinyl, or sulfonyl; R1 and R2 are independently hydrogen, halogen, amino, C1 to C4 alkyl, C1 to C4 alkylthio, C1 to C4 alkoxy, thiol, C, to C4 alkylsulfinyl, C1 to C4 alkylsulfonyl, trifluoromethyl, trifluoromethylthio, cyano, nitro, aralkyl, hydroxyalkyl, C1 to C4 alkylamino, dialkylamino wherein each alkyl group has 1 to 4 carbons, or R1 and R2 are joined together to form a polymethylene chain of 3 or 4 carbon atoms, with or without a hydroxy or keto functionality; X is O, N-R3, wherein R3 is hydrogen, C1 to C4 alkyl, aryl, hydroxy, C1 to C4 alkoxy, C1 to C5 acyloxy, amino, C1 to C4 alkylamino or dialkylamino wherein each alkyl group has 1 to 4 carbons; or a group of the formula: wherein each Y is independently O or S or NR6 wherein R6 is H, C1 to C4 alkyl, lower alkanoyl, benzoyl, trifluoroacetyl or CN; and R4 and R5 are each independently hydrogen or C1 to C4 alkyl and the broken line between R4 and R5 represents an optional bond when R4 and R5 are not hydrogen; and the pharmaceutically acceptable salts thereof. These compounds are useful for antagonizing the activity of prostaglandins in a mammal.

  本发明涉及式中的化合物： 式中 Z 是硫代、亚砜基或磺酰基； R1 和 R2 独立地为氢、卤素、氨基、C1 至 C4 烷基、C1 至 C4 烷硫基、C1 至 C4 烷氧基、硫醇、C, 至 C4 烷基亚磺酰基、C1 至 C4 烷基磺酰基、三氟甲基、三氟甲基硫代、氰基、硝基、芳烷基、羟基烷基、C1 至 C4 烷基氨基、二烷基氨基，其中 C1 至 C4 烷基为卤素、羟烷基、C1 至 C4 烷基氨基、二烷基氨基，其中每个烷基具有 1 至 4 个碳原子，或 R1 和 R2 连接在一起形成 3 或 4 个碳原子的多亚甲基链，具有或不具有羟基或酮官能团； X 是 O、N-R3，其中 R3 是氢、C1 至 C4 烷基、芳基、羟基、C1 至 C4 烷氧基、C1 至 C5 乙酰氧基、氨基、C1 至 C4 烷基氨基或二烷基氨基（其中每个烷基具有 1 至 4 个碳原子）；或式中的基团： 其中每个 Y 独立地为 O 或 S 或 NR6，其中 R6 为 H、C1 至 C4 烷基、低级烷酰基、苯甲酰基、三氟乙酰基或 CN；R4 和 R5 独立地为氢或 C1 至 C4 烷基，当 R4 和 R5 不是氢时，R4 和 R5 之间的断线代表任选键；及其药学上可接受的盐。 这些化合物可用于拮抗哺乳动物体内前列腺素的活性。
• Cardiovascular composition
  申请人：MERCK FROSST CANADA INC.

  公开号：EP0166257A2

  公开（公告）日：1986-01-02

  A cardiovascular composition is disclosed which comprises a dibenzo-thiepin compound having the formula wherein: X is a C1-C4 hydrocarbon group, optionally containing O, N or CO; Z is S, SO, S02, CO, CR4R5 wherein R4 and R5 taken together form the group =O or =CHR6 wherein R6 is hydrogen or phenyl; R1 is, e.g., 5-tetrazolyl, 5-tetrazolylmethyl, and wherein m is an integer of from 0 to 4 and R7 is, e.g., hydroxy or loweralkoxy; R2 and R3 can each independently be hydrogen, halogen (F, Cl, Br or I), nitro, loweralkyl, amino, N-loweralkylamino, N,N-diloweralkylamino, loweralkanoyl, hydroxy, loweralkoxy, lower acyloxy, loweralkylthio, trifluoromethylthio, loweralkylsulfinyl, loweralkylsulfonyl, trifluoromethyl, or R2 and R3, when bonded to adjacent carbon atoms, can be joined to form a 5- or 6-membered hydrocarbon ring which can optionally contain a double bond, a carbonyl group, or a hydroxyl group; or a pharmaceutically acceptable salt thereof. The composition can additionally comprise an angiotensin converting enzyme (ACE) inhibitor. These compositions represent a novel therapeutic approach to thromboembolic diseases in man.

  本发明公开了一种心血管组合物，该组合物包含一种二苯并噻吩化合物，其式为 其中X是C1-C4烃基，可选含有O、N或CO； Z是S、SO、S02、CO、CR4R5，其中R4和R5共同形成基团=O或=CHR6，其中R6是氢或苯基； R1是5-四唑基、5-四唑甲基，以及 其中 m 是 0 至 4 的整数，R7 是，例如、羟基或低级烷氧基；低级烷基磺酰基、三氟甲基，或 R2 和 R3 与相邻碳原子结合时可形成 5 或 6 元烃环，该环可选择含有双键、羰基或羟基；或其药学上可接受的盐。组合物还可以包含血管紧张素转换酶（ACE）抑制剂。这些组合物代表了一种治疗人类血栓栓塞性疾病的新方法。
• Indole-2-alkanoic acids and their use as prostaglandin antagonists
  申请人：MERCK FROSST CANADA INC.

  公开号：EP0166591A2

  公开（公告）日：1986-01-02

  Compounds of the formula I where R1 is H or alkyl of 1 to 6 carbons or R1 and R8 taken together form a group (CH2)v wherein v is 1 to 7; R2 is where each R8 is independently H, OH, C1 to C4-O-alkyl or alkyl of 1 to 4 carbons; or an R1 and an R8 taken together form a group (CH2)v wherein v is 1 to 7, R9 is COOR1; CH2OH; CHO; tetrazole; NHSO2R10 wherein R10 is OH, alkyl or alkoxy of 1 to 6 carbons, perhaloalkyl of 1 to 6 carbons, phenyl or phenyl substituted by alkyl or alkoxy groups of 1 to 3 carbons, halogen, hydroxy, COOH, CN, formyl or acyl of 1 to 6 carbons; CONHSO2R10; hydroxymethylketone; CN; or CON(R8)2; X is O; S; SO; S02; NR11 wherein R11 is H, alkyl of 1 to 6 carbons, acyl of 1 to 6 carbons, CN; CR1R8; or the unit wherein the dotted line represents an optical triple bond and in which the R1 and R8 substituents are absent when a triple bond is present; r and q are each independently 0 to 5 and p is 0 or 1 provided that the total of p, q and r is 2 to 6; R3 is H, alkyl of 1 to 6 carbons; phenyl or phenyl substituted by R4; or C1 to C4 alkylphenyl or C1 to C4 alkylphenyl in which the phenyl is substituted by R4; R4, R5, R6 and R7 are each independently selected from: (1) hydrogen; (2) alkyl having 1 to 6 carbon atoms; (3) alkenyl having 2 to 6 carbon atoms; (4) -(CH2)nM wherein n is 0 to 3 and M is a) OR12; b) halogen; c) CF3; d) SR12; e) phenyl or substituted phenyl wherein substituted phenyl is as defined below in the definition of R12; f) COOR13; g) h) tetrazole; i) wherein R15 is C1 to C6 alkyl, benzyl or phenyl; j) -NR13R13; k) -NHSO2R16 wherein R16 is C1 to C6 alkyl, phenyl, or CF3; I) m) -SOR12; n) -CON13R13; o) -SO2NR13R13; p) -SO2R12; q) N02; r) s) t) u) CN; each R12 independently is H; C1 to C6 alkyl; benzyl; phenyl or substituted phenyl wherein the substituents are C1 to C3 alkyl, halogen, CN, CF3, COOR13, CH2COOR13, C1 to C3 alkoxy, or C1 to C4 perfluoroalkyl; each R13 is independently H, phenyl or C1 to C6 alkyl; and, each R14 independently is H, (CH2)nCOOR13 wherein n is 0 to 4, C1 to C6 alkyl, CF3, phenyl, or substituted phenyl wherein substituted phenyl is as defined above in the definition of R12; and their pharmaceutically acceptable salts are useful as prostaglandin antagonists and are made into pharmaceutical compositions. Certain of the compounds are novel.

  式 I 的化合物 式中 R1 是 H 或 1 至 6 个碳原子的烷基，或 R1 和 R8 共同组成一个基团 (CH2)v，其中 v 为 1 至 7； R2 是 其中 每个 R8 独立地为 H、OH、C1 至 C4-O 烷基或 1 至 4 碳原子的烷基；或一个 R1 和一个 R8 共同形成一个基团 (CH2)v，其中 v 为 1 至 7、 R9 是 COOR1；CH2OH；CHO；四唑；NHSO2R10，其中 R10 是 OH、1-6 碳原子的烷基或烷氧基、1-6 碳原子的全卤代烷基、苯基或被 1-3 碳原子的烷基或烷氧基取代的苯基、卤素、羟基、COOH、CN、1-6 碳原子的甲酰基或酰基；CONHSO2R10；羟甲基酮；CN 或 CON(R8)2； X 是 O；S；SO；S02；NR11，其中 R11 是 H、1-6 碳原子的烷基、1-6 碳原子的酰基、CN；CR1R8； 或单元 其中虚线代表光学三键，当存在三键时，R1 和 R8 取代基不存在； r 和 q 各自独立地为 0 至 5，p 为 0 或 1，条件是 p、q 和 r 的总和为 2 至 6； R3 是 H、1 至 6 碳原子的烷基；苯基或被 R4 取代的苯基；或 C1 至 C4 烷基苯基或苯基被 R4 取代的 C1 至 C4 烷基苯基； R4、R5、R6 和 R7 各自独立地选自以下各项： (1) 氢 (2) 具有 1 至 6 个碳原子的烷基 (3) 具有 2 至 6 个碳原子的烯基； (4) -(CH2)nM 其中 n 为 0 至 3，M 为 a) OR12 b) 卤素 c) CF3 d) SR12 e) 苯基或取代苯基，其中取代苯基的定义见下文 R12 的定义； f) COOR13 g) h) 四氮唑 i) 其中 R15 为 C1 至 C6 烷基、苄基或苯基； j) -NR13R13 k) -NHSO2R16 其中 R16 是 C1 至 C6 烷基、苯基或 CF3； I) m) -SOR12 n) -CON13R13 o) -SO2NR13R13； p) -SO2R12 q) N02； r) s) t) u) CN； 每个 R12 独立地为 H、C1-C6 烷基、苄基、苯基或取代苯基，其中取代基为 C1-C3 烷基、卤素、CN、CF3、COOR13、CH2COOR13、C1-C3 烷氧基或 C1-C4 全氟烷基； 每个 R13 独立地是 H、苯基或 C1 至 C6 烷基；以及 每个 R14 独立地是 H、(CH2)nCOOR13（其中 n 为 0 至 4）、C1 至 C6 烷基、CF3、苯基或取代的苯基（其中取代的苯基如上文 R12 定义中所定义）； 及其药学上可接受的盐类可用作前列腺素拮抗剂并制成药物组合物。某些化合物是新型的。